WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential ...

VANCOUVER, British Columbia, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Q2 Metals Corp. (TSX.V: QTWO | OTCQB: QUEXF | FSE: 458) (“Q2” or the “Company”) is pleased to announce the appointment of Director Keith Phillips to the role of Executive Chair of the Board of Directors of the Company, effective immediately. Mr. Phillips joined the board of Q2 Metals in October 2025 after serving as Chief Executive Officer of Piedmont Lithium (“Piedmont”) from its inception in 2017 to its merger with Sayona Mining in 2025. Under ...

Gear up for game day, Sunday, February 8, 2026, with ultimate fan experiences, beer, wings, whiskey, and more at SweetWater Brewing Co., Montauk Brewing Co., Breckenridge Brewery, Blue Point Brewing Co., 10 Barrel Brewing Co., Hop Valley Brewing Co., Terrapin Beer Co., and Atwater BreweryNEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company, is gearing up for the biggest Sunday in sports as its craft beer ...

Brings more than 25 years of biopharma business development and corporate strategy expertiseBOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio’s business development strategy and execution, with responsibility for licensing, ...

Announces new $50 million share repurchase authorizationMOUNT LAUREL, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- J & J Snack Foods Corp. (Nasdaq: JJSF) today reported financial results for the first quarter ended December 27, 2025. First QuarterActuals$ v. LY% v. LYNet Sales$343.8M$(18.8M)(5.2%)<td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border ...

ST. LOUIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”), a holding company operating in the global proactive wellness category, today reported results for the first fiscal quarter ended December 31, 2025. Highlights: First quarter net sales of $537.3 million, up 1% year-over-yearOperating profit of $78.5 million, net earnings of $43.7 million and Adjusted EBITDA* of $90.3 millionNarrowed fiscal year 2026 net sales outlook of $2.41-$2.46 billion and Adjusted EBITDA* outloo ...

PALO ALTO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) will present a live audio webcast of a conference call to review financial results for the first fiscal quarter ended January 31, 2026 on Tuesday, Feb 24, 2026 at 5:00 p.m. ET / 2:00 p.m. PT. The webcast will be available at www.hp.com/investor/2026Q1Webcast. A replay of the audio webcast will be available at the same website shortly after the call and will remain available for approximately one year. About HP Inc. HP Inc. (NYSE: HPQ) ...

MONTREAL, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Harfang Exploration Inc. (TSX-V: HAR) (“Harfang” or the “Company”) announces fully-funded winter exploration plans for its portfolio of wholly-owned projects located in Eeyou Istchee James Bay, Québec, and in Ontario (see Figure 1). HIGHLIGHTS At Serpent, the Company will initiate a maiden diamond drilling program of approximately 10 holes totalling an estimated 1,500 metres focused on Mista, a 650-metre-long Cu-Au-Ag target that has never been drilled. The 3-week ...

Cardiac dosing limit removed and path forward to dose selection identifiedLONDON and PHILADELPHIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosin ...

Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company deve ...